SYNAPS Dx (SDx) is pleased to present “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease (AD),” at the Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, May 15-18, 2022, in National Harbor, Maryland.
Our implicit preference study indicates that 90% of physicians would routinely use the results of DISCERN™, a diagnostic test that assesses the factors directly related to the formation of synaptic connections in the brain impacting loss of memory and cognition in people living with AD, as well as regulators of amyloid plaque and tau formation, which are hallmarks of AD at autopsy.
Our study showed that DISCERN was an important attribute in physician decision-making and, compared to no DISCERN test, a positive result was associated with significantly higher clinician confidence in an AD diagnosis, even earlier in the disease. This result confirms the test’s value as the most promising breakthrough for early diagnosis of AD.
DISCERN, which has 95% sensitivity and 95% specificity in the diagnosis and management of AD, combines three biomarkers: Morphometric Imaging to measure fibroblasts’ ability to form networks; Protein Kinase C ε to measure synaptic growth; and AD-Index to measure phosphorylation of Erk1 and Erk2 in response to bradykinin. The study also found that a positive DISCERN test was associated with significantly higher odds of prescribing disease modifying agents for AD, with the MMSE score being the most important attribute in the decision to refer a patient to a neurologist.
See You at ISPOR
We are very excited to be part of this important event and to bring an innovative and effective test that has the potential to impact future health economics and outcomes research (HEOR) in patient-driven digital healthcare systems.
This year, ISPOR’s theme will be a “green thread” that is woven throughout the event to bring a fresh and holistic view into the future of HEOR in patient-driven digital healthcare systems.
To learn more visit here.